Molecular upstaging based on paraffin-embedded sentinel lymph nodes: Ten-year follow-up confirms prognostic utility in melanoma patients

Annals of Surgery

Volumn 253, Issue 1, 2011, Pages 116-122

  Nicholl, Michael B ^a,b   Elashoff, David ^a   Takeuchi, Hiroya ^a   Morton, Donald L ^b   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b Division of Surgical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MART 1 PROTEIN; MELANOMA ANTIGEN 2; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RECURRENCE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICROMETASTASIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY;

AGED; ANTIGENS, NEOPLASM; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASM PROTEINS; NEOPLASM STAGING; PAIRED BOX TRANSCRIPTION FACTORS; PARAFFIN EMBEDDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78751622090     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181fca894     Document Type: Article

References (38)

1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16): 3622-3634.
3. Morton DL, Wen DR, Wong JH, et al. Technical details of intraopera-tive lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4): 392-399.
4. Bostick P, Essner R, Glass E, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg. 1999;134(1):43-49.
5. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lym-phadenectomy Trial Group. Ann Surg. 1999;230(4):453-463; discussion 463-465.
6. Leong SP. Sentinel lymph node mapping and selective lymphadenectomy: the standard of care for melanoma. Curr Treat Options Oncol. 2004;5(3):185-194.
7. Sondak VK, Zager JS, Messina JL, et al. Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol. 2007;5(6):483-490.
8. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-1317.
9. Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12(6):429-439.
10. Karim RZ, Scolyer RA, Li W, et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg. 2008;247(6):1003-1010.
11. Thompson JF, Stretch JR, Uren RF, et al. Sentinel node biopsy for melanoma: where have we been and where are we going? Ann Surg Oncol. 2004;11(3)(suppl):147S-151S.
12. Zogakis TG, Essner R, Wang HJ, et al. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol. 2007;14(5):1604-1611.
13. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22(13):2671-2680.
14. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 1999;17(10):3238-3244.
15. Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol. 2003;21(19):3566-3572.
16. Takeuchi H, Kuo C, Morton DL, et al. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res. 2003;63(2):441-448.
17. Zogakis TG, EssnerR,Wang HJ,etal. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg. 2005;140(9):865-871; discussion 871-872.
18. Hoon DS, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 1995;13(8):2109-2116.
19. O'Connell CD, Juhasz A, Kuo C, et al. Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence. Clin Chem. 1998;44(6, Pt 1):1161-1169.
20. Sarantou T, Chi DD, Garrison DA, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res. 1997;57(7): 1371-1376.
21. Hilari JM, Mangas C, Xi L, et al. Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR. Ann Surg Oncol. 2009;16(1):177-185.
22. Mangas C, Hilari JM, Paradelo C, et al. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase- polymerase chain reaction for tyrosinase in melanoma patients. Ann Surg Oncol. 2006;13(7):910-918.
23. Mocellin S, Hoon DS, Pilati P, et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol. 2007;25(12):1588-1595.
24. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91(9):3515-3519.
25. Miyashiro I, Kuo C, Huynh K, et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem. 2001;47(3):505-512.
26. Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60(8): 2253-2257.
27. Koyanagi K, Kuo C, Nakagawa T, et al. Multimarker quantitative realtime PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem. 2005;51(6): 981-988.
28. Koyanagi K, O'Day SJ, Gonzalez R, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005;23(31): 8057-8064.
29. Tsuchida T, Saxton RE, Morton DL, et al. Gangliosides of human melanoma. J Natl Cancer Inst. 1987;78(1):45-54.
30. Tsuchida T, Saxton RE, Irie RF. Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst. 1987;78(1):55-60.
31. Kuo CT, Bostick PJ, Irie RF, et al. Assessment of messenger RNA of beta 1->4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma. Clin Cancer Res. 1998;4(2):411-418.
32. Maschhoff KL, Baldwin HS. Molecular determinants of neural crest migration. Am J Med Genet. 2000;97(4):280-288.
33. Scholl FA, Kamarashev J, Murmann OV, et al. PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res. 2001;61(3):823-826.
34. Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol. 2009:1-13.
35. Wang Q, Fang WH, Krupinski J, et al. Pax genes in embryogenesis and onco-genesis. J Cell Mol Med. 2008;12(6A):2281-2294.
36. Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer. 1999;86(4): 617-627.
37. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol. 2006;24(18):2849-2857.
38. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976-983.